USPTO Examiner GONZALEZ LUISALBERTO - Art Unit 1624

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
186257161,3-BIS(NAPHTHALEN-1-YLOXY)PROPAN-2-ONE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)April 2024June 2024Allow200NoNo
18609790PHARMACEUTICAL COMPOSITIONSMarch 2024November 2024Allow811YesNo
18608756DOSAGE FORMS OF MIRDAMETINIBMarch 2024March 2025Abandon1210NoNo
18595206ASYMMETRIC ALLYL TRYPTAMINESMarch 2024October 2024Allow811YesNo
18435547N-[(4,6-DIMETHYLPYRIMIDIN-2-YL)CARBAMOTHIOYL] PYRIDINE-3-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)February 2024August 2024Allow710YesNo
184303972-(1H-IMIDAZOLE-1-CARBONYL)BENZOIC ACID AS AN ANTICANCER COMPOUNDFebruary 2024August 2024Allow610NoNo
185116631,3-BIS(NAPHTHALEN-1-YLOXY)PROPAN-2-ONE AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)November 2023March 2024Allow410YesNo
18486910N-[(4,6-DIMETHYLPYRIMIDIN-2-YL)CARBAMOTHIOYL] PYRIDINE-3-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)October 2023April 2024Allow611YesNo
18378255N'-(2-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS ANTIMICROBIAL COMPOUNDOctober 2023March 2024Allow511YesNo
183691322-(1H-IMIDAZOLE-1-CARBONYL)BENZOIC ACID AS AN ANTICANCER COMPOUNDSeptember 2023March 2025Abandon1831NoNo
18463157SOLID FORMS OF ALPHA-1062 GLUCONATESeptember 2023July 2024Allow1001YesNo
18240886PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOFAugust 2023September 2024Allow1310YesNo
182395393,3'-(PIPERAZINE-1,4-DIYL)BIS(1-(NAPHTHALEN-2-YLOXY)PROPAN-2-OL) AS INSECTICIDAL AGENTAugust 2023January 2024Allow511NoNo
18456379LYOPHILIZED PHARMACEUTICAL COMPOSITION AND USES OF A CRYSTALLIZED FORM OF LURBINECTEDINAugust 2023August 2024Abandon1211YesNo
18225244COMPOSITIONS AND METHODS FOR TREATING EPILEPSYJuly 2023April 2024Allow911NoNo
18225234COMPOSITIONS AND METHODS FOR TREATING EPILEPSYJuly 2023February 2024Allow721YesNo
18309795Compositions and Methods for Treating COVID-19 and/or Acute Respiratory Failure and/or Acute Respiratory Distress Syndrome Using Tetrahydrocannabinol and Compositions Including SameApril 2023May 2024Abandon1311NoNo
18297316IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOFApril 2023September 2023Allow510NoNo
18245624OLAPARIB OXALIC ACID COCRYSTALS AND THEIR PHARMACEUTICAL USEMarch 2023February 2024Allow1110YesNo
18044066CANCER THERAPEUTIC COMPOSITIONS AND METHODS TARGETING DNASE1L3March 2023May 2025Allow2640YesNo
18110261PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS AND USES THEREOFFebruary 2023June 2023Allow410YesNo
18154205CRYSTALLINE FORMS OF 3-(5-(2-HYDROXY-2-METHYLPROPOXY)-6-METHYLPYRAZIN-2-YL)-1H-INDOLE-7-CARBONITRILEJanuary 2023August 2024Allow1901YesNo
18077350COMPOSITIONS COMPRISING COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE WITH TROMETHAMINE AND METHODS OF USEDecember 2022July 2024Abandon2020NoNo
17922581SARS-CoV-2 Antiviral Pharmaceutical Composition and Application ThereofOctober 2022November 2023Abandon1210NoNo
17934884BORTEZOMIB COMPOSITIONSSeptember 2022December 2023Abandon1521YesNo
17818026Treatment for Diseases of AgingAugust 2022April 2025Abandon3321YesNo
17876096PHARMACEUTICAL COMPOSITIONS AND CRUSHABLE TABLETS INCLUDING AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USESJuly 2022January 2024Allow1721NoNo
17867352METHODS OF MANUFACTURING 14,15-EPOXYEICOSATRIENOIC ACID ANALOGS AND IMPROVED THERAPEUTIC DELIVERY OF SAMEJuly 2022December 2023Allow1721NoNo
17787510FORMULATIONS FOR USE IN THE TREATMENT OF DIFFERENT TYPES OF ADDICTIONS AND DEPENDENCE ON ADDICTIVE SUBSTANCESJune 2022November 2023Abandon1710NoNo
17839486CRYSTALLINE BORTEZOMIB PROCESSJune 2022January 2024Allow1921YesNo
17777985NEW SOLID STATE FORM OF LURBINECTEDINMay 2022December 2024Abandon3101NoNo
17663669Novel Pharmaceutical Composition of Dimethylguanidino Valeric Acid and Plant Flavonoids for Treating Chronic Inflammatory Diseases and CancerMay 2022June 2023Allow1301YesNo
17739104ORONASAL CBD FORMULATIONS AND USES THEREOFMay 2022October 2024Abandon2901NoNo
17735276JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF PRURIGO NODULARISMay 2022December 2024Allow3140YesNo
17730129COMPOSITION FOR ZINC IONOPHORIC INFLUX AND TREATING INFLAMMATIONApril 2022April 2025Abandon3640YesNo
17728769Method of simultaneously treating viral disease caused coronavirus, its variants and mutants using a pharmaceutical micronutrient compositionApril 2022April 2024Abandon2411YesNo
17714553HEALTH SUPPLEMENTApril 2022January 2025Abandon3421YesNo
17591186CRYSTALLINE FORMS OF A CYCLIN-DEPENDENT KINASE INHIBITORFebruary 2022March 2024Abandon2510NoNo
17587380TREATMENTS FOR SKIN CONDITIONSJanuary 2022December 2024Abandon3530NoNo
17577612INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS FOR CANCER IMMUNOTHERAPYJanuary 2022January 2024Abandon2401NoNo
17575025SOLID FORMS OF ALPHA-1062 GLUCONATEJanuary 2022August 2023Allow1920NoNo
17571715ORGANIC ACYL HALOSULFONAMIDE BIOCIDE COMPOSITIONS AND METHODS OF MAKING AND USING THE COMPOSITIONSJanuary 2022May 2024Abandon2811NoNo
17564490COMPOSITIONS FOR THE MANAGEMENT OF DEMYELINATING DISORDERSDecember 2021May 2025Abandon4041YesNo
17556098PARENTERAL CANNABINOID FORMULATIONS AND USES THEREOFDecember 2021April 2024Allow2831YesNo
17617453Antibacterial Dosage Regime Using CannabinoidsDecember 2021June 2025Abandon4201NoNo
17617322TRIAZOLE CARBOXYLIC ACIDS AS LPA ANTAGONISTSDecember 2021April 2025Allow4011NoNo
17535125MODULATION OF MOLECULAR MARKERS USING S-EQUOLNovember 2021April 2024Allow2921YesNo
17518590ANTIOXIDANT FOR USE IN TREATMENT FOR RIBENovember 2021August 2024Abandon3330NoNo
17517197COMPOSITIONS COMPRISING VITAMINS/MINERALS IN A POLYPHENOLIC MATRIX, METHODS AND USES THEREOFNovember 2021October 2023Allow2410YesNo
17516400AQUEOUS COMPOSITIONS OF BORTEZOMIBNovember 2021March 2024Allow2820YesNo
17501667METHODS AND COMPOSITIONS FOR TREATING HUMAN PAPILLOMAVIRUS (HPV)-INDUCED CANCERSOctober 2021April 2024Abandon3020NoNo
17594293HETEROCYCLIC COMPOUNDS AND USES THEREOFOctober 2021May 2025Abandon4401NoNo
17492978MRGX2 ANTAGONISTSOctober 2021December 2023Allow2611NoNo
17490492Combination Drug Substance of Polyamine Transport Inhibitor and DFMOSeptember 2021September 2023Allow2320YesNo
17488430Halogenated Xanthenes as Vaccine AdjuvantsSeptember 2021December 2023Allow2630NoNo
17485858sGC STIMULATORSSeptember 2021June 2025Allow4441YesNo
17486065COMPOSITION COMPRISING CAPSAICIN OR A CAPSACINOID FOR POSTOPERATIVE PAIN CONTROLSeptember 2021June 2025Abandon4511NoNo
17593650N-[l-(5-BROMO-2-PYRIMIDIN-2-YL-1,2,4-TRIAZOL-3-YL)ETHYL]-2-CYCLOPROPYL-6-(TRIFLUOROMETHYL)PYRIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INSECTICIDESSeptember 2021March 2025Abandon4111NoNo
17482369TOPICAL CROTON LECHLERI COMPOSITIONS AND THEIR USE IN THE TREATMENT OF A BACTERIAL COLONIZATION OR PRIMARY OR SECONDARY BACTERIAL INFECTION OF AN UNDERLYING SKIN DISORDERSeptember 2021June 2025Allow4540YesNo
17438767FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASESSeptember 2021March 2025Abandon4201NoNo
174690635-METHOXY-N,N-DIMETHYLTRYPTAMINE CRYSTALLINE FORMSSeptember 2021May 2023Allow2010NoNo
17435230PHARMACEUTICAL COMPOSITION COMPRISING a-GALACTOSYLCERAMIDE AND/OR DENDRITIC CELLS PULSED WITH a-GALACTOSYLCERAMIDEAugust 2021March 2025Abandon4201NoNo
17445792POLYMORPHS OF AN SSAO INHIBITORAugust 2021April 2023Allow1910NoNo
17432589COMPOUNDS USEFUL FOR INHIBITING RAF DIMERSAugust 2021June 2025Allow4611YesNo
17430346COMBINATION THERAPIES FOR USE IN TREATING CANCERAugust 2021January 2025Abandon4201NoNo
17430065METHODS AND COMPOSITIONS FOR INHIBITING THE NLRP3 INFLAMMASOME AND/OR LON PROTEASEAugust 2021March 2025Allow4311YesNo
17429885SUBSTITUTED AMINO-THIOL AND AMINO-DISULFIDE COMPOUNDS, AND USES THEREOFAugust 2021April 2025Allow4421YesNo
17429438POLYMORPHS OF INTEGRASE INHIBITORAugust 2021September 2024Allow3801YesNo
17429269VALPROIC ACID COMPOUNDS AND WNT AGONISTS FOR TREATING EAR DISORDERSAugust 2021December 2024Abandon4101NoNo
17395254Methods and Compositions for Microdosing, Simulating Extended Release FormulationsAugust 2021July 2023Abandon2401NoNo
17427811THERAPEUTIC COMBINATIONS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASEAugust 2021November 2024Abandon4001NoNo
17443485USE OF A MIXTURE OF LAUROYL MACROGOLGLYCERIDE AND POLYETHYLENE GLYCOL AS AN EXCIPIENTJuly 2021March 2024Allow3220YesNo
17425124METHODS OF TREATING DISEASE WITH MAGL INHIBITORSJuly 2021December 2024Abandon4101NoNo
17353573ORONASAL CBD FORMULATIONS AND USES THEREOFJune 2021November 2023Abandon2911NoNo
17416064NITROGEN-CONTAINING FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOFJune 2021October 2024Abandon4001NoNo
17312480ARGINASE INHIBITORS AND METHODS OF USEJune 2021September 2024Allow3911NoNo
17338283PERSONALIZED METHODS OF TREATING CANCERJune 2021July 2024Allow3730YesNo
17297913PHARMACEUTICAL APPLICATION OF DIMYRICETIN-BASED DISELENIDEMay 2021June 2025Abandon4821NoNo
17291793COMBINATION OF PRMT5 INHIBITORS AND BCL-2 INHIBITORSMay 2021December 2023Abandon3210NoNo
17290939DIHYDROMYRICETIN WITH ANTI-ALCOHOLIC EFFECTMay 2021April 2025Abandon4720YesNo
17283843TREATMENT OF DISEASES ASSOCIATED WITH BILIARY SYSTEM DESTRUCTIONApril 2021April 2025Allow4811YesNo
17217524STIMULUS-RESPONSIVE ANTIOXIDANT CRYSTALS AND METHOD FOR THEIR PREPARATIONMarch 2021December 2023Allow3311YesNo
17279751AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREFOR AND USE THEREOFMarch 2021March 2025Allow4831YesNo
17211823FISETIN COMPOSITION AND A METHOD OF MAKING THE SAMEMarch 2021July 2023Abandon2810NoNo
17212723Uses of Halogenated Xanthenes in Oncology and VirologyMarch 2021March 2024Allow3531YesNo
17211778METHODS OF USING NITRIC OXIDE DONOR COMPOUNDS FOR TREATMENT OF COVID-19 AND OTHER INFECTIOUS DISEASESMarch 2021July 2023Allow2811YesNo
17279525MEDICAL APPLICATION OF PYRIMIDINE SULFONAMIDES DERIVATIVESMarch 2021December 2022Allow2110YesNo
17203758COMPOUND AND USE THEREOFMarch 2021July 2024Abandon4001NoNo
17200854AURORA KINASE INHIBITORS AND USES THEREOFMarch 2021May 2025Allow5031YesNo
17274600METHODS FOR THE TREATMENT OF NEUROFIBROMATOSISMarch 2021April 2025Abandon4951NoNo
17184350METHODS OF USING CANNABINOIDS FOR INHIBITING INDUCTION OF VIRULENCE IN ENTERIC PATHOGENSFebruary 2021May 2023Abandon2710NoNo
17173416GPX4 INHIBITOR IN COMBINATION WITH ANTICANCER AGENT FOR TREATING PROLIFERATIVE DISEASEFebruary 2021January 2024Allow3530NoNo
17168524CANNABINOID-CONTAINING EXTRACTS, FORMULATIONS, AND USES THEREOF FOR TREATING AMYOTROPHIC LATERAL SCLEROSISFebruary 2021December 2023Abandon3420NoNo
17261982INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTIONJanuary 2021January 2025Allow4821YesNo
17154261Crystalline Forms of Zuclomiphene CitrateJanuary 2021February 2023Allow2511NoNo
17260691HERBICIDAL MIXTURES COMPRISING ISOXAFLUTOLE, PYROXASULFONE AND AN IMIDAZOLINONE HERBICIDE; AND THEIR USE IN SOYBEAN AND COTTON CULTURESJanuary 2021May 2025Allow5221YesNo
17260124METHODS OF UPREGULATING TIPARP AS ANTICANCER STRATEGIESJanuary 2021April 2025Abandon5121NoNo
17252214DECREASING IMMUNE ACTIVITY THROUGH MODULATION OF POSTCELLULAR SIGNALING FACTORSDecember 2020September 2024Abandon4511NoNo
17058065CANNABIS-BASED COMPOSITIONS FOR THE TREATMENT OF AUTISTIC SPECTRUM DISORDERSNovember 2020April 2024Abandon4001NoNo
16952887Methods of Treating Brain Cancer and Related Diagnostic MethodsNovember 2020September 2023Abandon3411NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GONZALEZ, LUISALBERTO.

Strategic Value of Filing an Appeal

Total Appeal Filings
1
Allowed After Appeal Filing
1
(100.0%)
Not Allowed After Appeal Filing
0
(0.0%)
Filing Benefit Percentile
95.4%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner GONZALEZ, LUISALBERTO - Prosecution Strategy Guide

Executive Summary

Examiner GONZALEZ, LUISALBERTO works in Art Unit 1624 and has examined 110 patent applications in our dataset. With an allowance rate of 53.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner GONZALEZ, LUISALBERTO's allowance rate of 53.6% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by GONZALEZ, LUISALBERTO receive 1.51 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GONZALEZ, LUISALBERTO is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +53.5% benefit to allowance rate for applications examined by GONZALEZ, LUISALBERTO. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 38.2% of applications are subsequently allowed. This success rate is in the 85% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 35.0% of cases where such amendments are filed. This entry rate is in the 44% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 29.4% are granted (fully or in part). This grant rate is in the 21% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 10.2% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.